Compare Emerson Electric Co. (EMR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Inovio Pharmaceuticals Inc — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Emerson Electric Co. is far larger — about 790.8× Inovio Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EMR | INO | |
|---|---|---|
Market Cap | $88.72B | $112.19M |
Volume | 2,355,255 | 3,201,278 |
Sector | Industrials | Health |
52-Week High | $164.38 | $2.60 |
52-Week Low | $123.30 | $0.66 |
Typical Hold Time | 81 Days | 43 Days |
Enterprise Value | $99.80B | $83.51M |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.06, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $165.90. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.84. Strong profitability is evident with a 53.16% gross margin and 13.83% net income margin, though valuation multiples like a P/E of 34.81 appear elevated. Recent news highlights momentum and Wall Street optimism.
EMR presents a favorable outlook with earnings momentum and analyst support, but risks include high valuation sensitivity and debt level increases. The stock offers potential upside to the price target, balanced by execution risks in a competitive industrial sector. Investors should weigh solid fundamentals against premium pricing.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
